PubMed Health⌕ Search

PubMed · 10399257

[In Process Citation]

Abstract

OBJECTIVE: The objective of this retrospective analysis was to compare the obstetrical procedures at premature birth and delivery at term. The aim was to show the influence of gestational time on mode of delivery and neonatal state. MATERIAL AND METHODS: 339 births from breech presentation between 1988-1990 were compared with premature births and deliveries at term. RESULTS: Frequency of breech presentation totalled 4.1%. 173 deliveries (51.7%) resulted vaginally, 26 cases (7.8%) with freeing of arms and 4 cases (1.2%) as extraction. Frequency of cesarean sections totalled 48.3%. The number of premature births reached in the group of breech presentation 23.1%. Births at term resulted with 58% predominantly vaginally (abdominally in 42%). Between the 31st and 36th gestational week the number of cesarean sections rose to 67.3%, in the 31st week it even reached 78.9%. The neonatal state was described with the help of Apgar-scores and umbilical cord-pH-values. The share of newborns with optimal Apgar-values after 1 minute (8-10) was in premature births with 36.5% only about half as large as in deliveries at term (77.6%). Only 9.6% of the children showed pH-values below 7.20. Number of newborns with these pH-values totalled in premature births in the 31st week 35.3%, for terms between the 31st and 36th week 15.6%, and declined in mature births to only 6.2%. CONCLUSIONS: Estimating the neonatal state of the group of breech presentations the vaginal birth should keep an equal rank in the delivery plan of a clinic. At the appraisal of the childlike early morbidity of a delivery group the number of premature newborns is decisive.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Schultz, A Jorde, G Morack. 1999. [In Process Citation]. https://pubmed.ncbi.nlm.nih.gov/10399257/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗